• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Keeping risk in context while rethinking the setting of asthma biologics in patient-centered care.

作者信息

Greenhawt Matthew, Shaker Marcus

机构信息

Section of Allergy and Immunology, Food Challenge and Research Unit, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.

Section of Allergy and Immunology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Dartmouth Geisel School of Medicine, Hanover, New Hampshire.

出版信息

Ann Allergy Asthma Immunol. 2020 Aug;125(2):124-125. doi: 10.1016/j.anai.2020.05.029. Epub 2020 Jun 1.

DOI:10.1016/j.anai.2020.05.029
PMID:32497713
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7263209/
Abstract
摘要

相似文献

1
Keeping risk in context while rethinking the setting of asthma biologics in patient-centered care.在以患者为中心的护理中重新思考哮喘生物制剂的应用时，要全面考虑风险因素。
Ann Allergy Asthma Immunol. 2020 Aug;125(2):124-125. doi: 10.1016/j.anai.2020.05.029. Epub 2020 Jun 1.
2
Choosing the right biologic for severe asthma: precision medicine through the lens of patient-centered decision making.为重度哮喘选择合适的生物制剂：以患者为中心的决策视角下的精准医学
Ann Allergy Asthma Immunol. 2019 Oct;123(4):331-332. doi: 10.1016/j.anai.2019.07.012. Epub 2019 Jul 24.
3
COVID-19 in a patient with severe asthma treated with Omalizumab.使用奥马珠单抗治疗的重度哮喘患者中的新型冠状病毒肺炎
Allergy. 2020 Oct;75(10):2705-2708. doi: 10.1111/all.14456. Epub 2020 Jun 27.
4
[Treatment of refractory asthma with antibodies].[用抗体治疗难治性哮喘]
Dtsch Med Wochenschr. 2016 Jun;141(11):790-3. doi: 10.1055/s-0042-107044. Epub 2016 Jun 2.
5
Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications.奥马珠单抗在美FDA 扩大适应证后用于儿科哮喘的应用。
Pharmacoepidemiol Drug Saf. 2024 Oct;33(10):e70009. doi: 10.1002/pds.70009.
6
Use of Biological Agents in Asthma: Pharmacoeconomic Lessons Learned From Omalizumab.生物制剂在哮喘治疗中的应用：从奥马珠单抗汲取的药物经济学经验教训。
Chest. 2017 Feb;151(2):249-251. doi: 10.1016/j.chest.2016.06.033.
7
A New Monoclonal Antibody Treats Severe Asthma.一种新型单克隆抗体可治疗重度哮喘。
Am J Nurs. 2016 Jul;116(7):24-5. doi: 10.1097/01.NAJ.0000484935.48100.ce.
8
Effects of omalizumab on T lymphocyte function in inner-city children with asthma.奥马珠单抗对城市儿童哮喘患者T淋巴细胞功能的影响。
Pediatr Allergy Immunol. 2016 May;27(3):328-31. doi: 10.1111/pai.12508. Epub 2016 Feb 18.
9
Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid-induced adrenal suppression.奥马珠单抗与变应原免疫疗法治疗1例哮喘合并吸入性糖皮质激素所致肾上腺抑制患者
Ann Allergy Asthma Immunol. 2016 Sep;117(3):335-7. doi: 10.1016/j.anai.2016.07.017.
10
The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.波兰变态反应学会关于使用奥马珠单抗治疗严重IgE介导的过敏性哮喘的治疗方案必要变更的声明。
Pneumonol Alergol Pol. 2015;83(4):335-8. doi: 10.5603/PiAP.2015.0053.

引用本文的文献

1
Anaphylaxis knowledge gaps and future research priorities: A consensus report.过敏反应知识差距和未来研究重点：共识报告。
J Allergy Clin Immunol. 2022 Mar;149(3):999-1009. doi: 10.1016/j.jaci.2021.07.035. Epub 2021 Aug 12.
2
What the COVID-19 Pandemic Can Teach Us About Resource Stewardship and Quality in Health Care.从 COVID-19 大流行中我们能学到的医疗资源管理和医疗质量相关知识。
J Allergy Clin Immunol Pract. 2021 Feb;9(2):608-612. doi: 10.1016/j.jaip.2020.11.033. Epub 2020 Nov 27.

本文引用的文献

1
Engaging patient partners in state-of-the-art allergy care: Finding balance when discussing risk.让患者伙伴参与最先进的过敏护理：在讨论风险时找到平衡。
Ann Allergy Asthma Immunol. 2020 Sep;125(3):252-261. doi: 10.1016/j.anai.2020.01.029. Epub 2020 Feb 7.
2
Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab.评估奥马珠单抗和美泊利珠单抗在诊所与家庭管理中的健康和经济效益。
J Allergy Clin Immunol Pract. 2020 Feb;8(2):565-572. doi: 10.1016/j.jaip.2019.09.037. Epub 2019 Oct 15.
3
Trends and Disparities in Asthma Biologic Use in the United States.美国哮喘生物制剂使用的趋势和差异。
J Allergy Clin Immunol Pract. 2020 Feb;8(2):549-554.e1. doi: 10.1016/j.jaip.2019.08.024. Epub 2019 Aug 28.
4
Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population.美国医疗保险人群中哮喘患者奥马珠单抗治疗模式。
J Allergy Clin Immunol Pract. 2020 Feb;8(2):507-515.e10. doi: 10.1016/j.jaip.2019.07.011. Epub 2019 Jul 20.
5
Selecting the right biologic for your patients with severe asthma.为严重哮喘患者选择合适的生物制剂。
Ann Allergy Asthma Immunol. 2018 Oct;121(4):406-413. doi: 10.1016/j.anai.2018.07.033. Epub 2018 Jul 27.